tiprankstipranks
Nkarta announces updated clinical data on NKX019
The Fly

Nkarta announces updated clinical data on NKX019

Nkarta announced positive updated data from its Phase 1 dose escalation study of NKX019 as monotherapy to treat patients with relapsed or refractory non-Hodgkin lymphoma, NHL. Nkarta plans to provide updates from the NKX019 program, including data from the dose expansion cohorts, in 2023. Evaluating NKX019 in r/r B cell malignancies: NKX019 is an allogeneic, cryopreserved, off-the-shelf cancer immunotherapy candidate that uses NK cells engineered to target the B-cell antigen CD19, a clinically validated target for B-cell cancer therapies. The NKX019 Phase 1 study is evaluating the safety and anti-tumor activity of NKX019 as a multi-dose, multi-cycle therapy in patients with r/r B cell malignancies. As of November 28, 2022, 19 patients were enrolled and dosed. Fourteen patients entered the study with a diagnosis of non-Hodgkin lymphoma, 7 of which were aggressive large B cell lymphoma. Safety in NKX019: NKX019 was well tolerated. No ICANS, GvHD, or greater thanGr3 CRS were observed in the study. No dose-limiting toxicities were observed. Five patients developed fever within 8 hours of NKX019 infusion, and each resolved within 24 hours. 2 of the 5 patients were assessed to have infusion-related reactions, 2 patients were assessed to have CRS, despite the rapid onset and rapid resolution not common in CRS, and one patient had both entities described in two separate cycles. The most common higher-grade adverse events were myelosuppression. Clinical Activity in NXK019 : Nineteen patients who received NKX019 were assessed. In the two highest dose cohorts, 8 out of 10 patients with NHL achieved an objective response and 7 out of 10 achieved a complete response. 5 of 6 patients with NHL in the cohort receiving 3 doses of 1 billion cells achieved a response, and 4 of 6 achieved a complete response. 3 of 4 patients with NHL in the cohort receiving 3 doses of 1.5 billion cells achieved a response and a complete response. For all cohorts in the dose finding portion, 10 of 14 patients with NHL achieved an objective response and 8 of 14 achieved a complete response. 3 patients with ALL and 2 patients with CLL were treated, with no response observed.

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on NKTX:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles